- Home
- TOYO vs RLMD Comparison
TOYO vs RLMD Comparison
Compare TOYO & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOYO
- RLMD
- Stock Information
- Founded
- TOYO 2022
- RLMD 2004
- Country
- TOYO Japan
- RLMD United States
- Employees
- TOYO N/A
- RLMD N/A
- Industry
- TOYO
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- TOYO
- RLMD Health Care
- Exchange
- TOYO NYSE
- RLMD Nasdaq
- Market Cap
- TOYO 115.2M
- RLMD 110.6M
- IPO Year
- TOYO N/A
- RLMD N/A
- Fundamental
- Price
- TOYO $3.04
- RLMD $3.01
- Analyst Decision
- TOYO
- RLMD Hold
- Analyst Count
- TOYO 0
- RLMD 2
- Target Price
- TOYO N/A
- RLMD $7.50
- AVG Volume (30 Days)
- TOYO 23.4K
- RLMD 117.3K
- Earning Date
- TOYO 08-21-2024
- RLMD 11-07-2024
- Dividend Yield
- TOYO N/A
- RLMD N/A
- EPS Growth
- TOYO N/A
- RLMD N/A
- EPS
- TOYO 0.76
- RLMD N/A
- Revenue
- TOYO $200,455,385.00
- RLMD N/A
- Revenue This Year
- TOYO N/A
- RLMD N/A
- Revenue Next Year
- TOYO N/A
- RLMD N/A
- P/E Ratio
- TOYO $3.97
- RLMD N/A
- Revenue Growth
- TOYO N/A
- RLMD N/A
- 52 Week Low
- TOYO $1.36
- RLMD $1.88
- 52 Week High
- TOYO $15.61
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- TOYO N/A
- RLMD 31.18
- Support Level
- TOYO N/A
- RLMD $3.06
- Resistance Level
- TOYO N/A
- RLMD $3.43
- Average True Range (ATR)
- TOYO 0.00
- RLMD 0.20
- MACD
- TOYO 0.00
- RLMD -0.05
- Stochastic Oscillator
- TOYO 0.00
- RLMD 6.61
About TOYO TOYO CO LTD
Toyo Co Ltd along with its subsidiaries is engaged in research and development, production, and sales of solar cells.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.